A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-COMPARATOR-CONTROLLED
CLINICAL STUDY OF ADJUVANT V940 (MRNA-4157) PLUS PEMBROLIZUMAB VERSUS ADJUVANT
PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH HIGH-RISK MUSCLE-INVASIVE
UROTHELIAL CARCINOMA POST-RADICAL RESECTION
- Registry ID
- V940-005
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2024-05-28
- Last update
- 2023-12-05
Conditions
Related clinical trials
- A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF LIVMONIPLIMAB IN COMBINATION WITH BUDIGALIMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CARCINOMA
- A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY OF
AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS PLACEBO PLUS
NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK
MUSCLE-INVASIVE UROTHELIAL CARCINOMA
- A PHASE II STUDY OF FLUORINE-148 (18F)-LABELED PSMA-1007 IN PATIENTS WITH KNOWN OR SUSPECTED METASTATIC PROSTATIC CARCINOMA
- "A PHASE 3 RANDOMIZED, DOUBLE BLIND STUDY OF PEMBROLIZUMAB PLUS GEMCITABINE/CISPLATIN VERSUS PLACEBO PLUS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED AND/OR UNRESECTABLE BILIARY TRACT CARCINOMA.
- A PHASE 1 A/2A COHORT DOSE ESCALATION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE AND PRELIMINARY ANTINEOPASTIC ACTIVITY OF AVID100, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY LINKED TO THE MAYTANSINOID OM 1
- A PHASE 1 STUDY OF ASP8374, AN IMMUNE CHECKPOINT INHIBITOR, AS A SINGLE AGENT IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CARCINOMA
View on source registry